Cargando…

Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”

Detalles Bibliográficos
Autor principal:	Wambier, Carlos Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779256/ https://www.ncbi.nlm.nih.gov/pubmed/33408021 http://dx.doi.org/10.1016/j.ijantimicag.2020.106175

Ejemplares similares

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
por: Gautret, Philippe, et al.
Publicado: (2021)

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
por: dos Santos, Marcelo Rodrigues
Publicado: (2021)

Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
por: Saad, Mohamed O
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
por: Gautret, Philippe, et al.
Publicado: (2020)

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial
por: Parra-Lara, Luis Gabriel, et al.
Publicado: (2021)

Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
por: Gautret, Philippe, et al.
Publicado: (2021)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV)
por: Sobngwi, Eugene, et al.
Publicado: (2023)

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
por: Molina, J.M., et al.
Publicado: (2020)

Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load
por: Nguyen, Tuan V.
Publicado: (2021)

Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
por: Fiolet, Thibault, et al.
Publicado: (2021)

Problems with the analysis in “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19”
por: Atkinson, J. Graham
Publicado: (2020)

Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature
por: Goldman, Jason D., et al.
Publicado: (2021)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response
por: Fiolet, Thibault, et al.
Publicado: (2021)

Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend
por: Hor, Chee Peng, et al.
Publicado: (2020)

Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
por: Gautret, Philippe, et al.
Publicado: (2021)

Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
por: Gautret, Philippe, et al.
Publicado: (2021)

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial
por: Fraser, Simon D., et al.
Publicado: (2020)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Lacout, Alexis, et al.
Publicado: (2021)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Million, Matthieu, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann
por: Gautret, Philippe, et al.
Publicado: (2021)

Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients
por: Lacout, Alexis, et al.
Publicado: (2021)

The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19
por: Sadasivam, Balakrishnan, et al.
Publicado: (2020)

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
por: Million, Matthieu, et al.
Publicado: (2021)

Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949
por: Rosendaal, Frits R.
Publicado: (2020)

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
por: Okour, Malek, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Methemoglobinemia following off-label use: case report
Publicado: (2020)

Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021)

D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial
por: Witters, Peter, et al.
Publicado: (2021)

Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial
por: Brown, Samuel M., et al.
Publicado: (2021)

Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis' by Fiolet et al.
por: Vedrines, Nicolas, et al.
Publicado: (2021)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
por: Cadegiani, F.A., et al.
Publicado: (2021)

Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin
por: Chang, David, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine/tocilizumab: QTc prolongation and off label use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_37gkg8gfu07ship56igd6668bg